Mainz Biomed starts a next-generation clinical trial for adenoma detection
Mainz Biomed NV launched eAArly DETECT 2, a U.S. feasibility study for its next-generation colorectal cancer (CRC) screening test....
Jon Napitupulu
Humacyte Plans IND Filing for Small-Diameter ATEV™ in 2025
Humacyte plans to submit an Investigational New Drug (IND) application to the FDA for its small-diameter (3.5mm) acellular tissue...
AI in Oncology to Hit $11.52B by 2030, with 29.4% CAGR
The global AI in oncology market, valued at US$1.92 billion in 2023, is projected to reach US$11.52 billion by...
Datroway® Approved for Metastatic Breast Cancer
Datopotamab deruxtecan (DATROWAY), a TROP2-directed antibody-drug conjugate (ADC), has received US approval for treating adults with unresectable or metastatic...
FDA Accepts Arrowhead’s New Drug Application for Plozasiran Treatment
Arrowhead Pharmaceuticals announced that the FDA accepted its New Drug Application (NDA) for plozasiran, a treatment for the rare...
Zai Lab’s KarXT for Schizophrenia Treatment Accepted by FDA
Zai Lab’s New Drug Application (NDA) for KarXT, a schizophrenia treatment for adults, has been accepted by China’s National...
Acalabrutinib Plus Chemoimmunotherapy Approved for Mantle Cell Lymphoma
The FDA has granted full approval to AstraZeneca’s CALQUENCE (acalabrutinib) combined with bendamustine and rituximab for first-line treatment of...
Enigma Biomedical & Neuraly Announce Research & Commercialization Deal
Neuraly Inc., a subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. signed a research license and commercialization...
Nasdaq Lists Disc Medicine Grant Under Rule 5635(c)(4)
Disc Medicine granted a new employee an equity award consisting of a stock option to purchase 35,000 shares and...
Shionogi’s S-892216: Breakthrough COVID-19 Antiviral for At-Risk Groups
Shionogi Inc. secured a $375 million agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop S-892216,...